NCT05046613Recruiting

Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant

Pfizer

Start Date

9/23/2021

Completion Date

4/30/2034

Summary

The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.

Eligibility Criteria

Age Range: No minimum to No maximum

Inclusion Criteria: * Pregnant women with migraine exposed to rimegepant: a diagnosis of migraine and at least 1 dose of rimegepant during pregnancy or just prior to pregnancy (up to 3 days prior to conception) * Pregnant women with migraine unexposed to rimegepant: a diagnosis of migraine and no exposure to Rimegepant before or during pregnancy Exclusion Criteria: • Women exposed to other calcitonin gene-related peptide (CGRP)antagonists (e.g., ubrogepant), CGRP monoclonal antibodies, or ditans (e.g., lasmiditan) at any time during pregnancy or just prior to pregnancy

Interventions

OTHER

Rimegepant

OTHER

Not taking Rimegepant

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Migraine

Locations

Evidera, a PPD business unit

Wilmington, North Carolina 28401

United States

Run studies, or work at a research site?

Corterve helps sites and sponsors reach patients who are looking for trials. It does not determine eligibility and does not promise an enrolment outcome.

For sponsors, CROs and sites

What Corterve sells to organisations, and the anti-kickback constraints it works within.

Services and published prices

Lay summaries for EU CTR Annex V, pre-screen filtration, recruitment-creative regulatory operations, feasibility reporting.

For research sites

One published licence rate, the same for every site, and the fees a site is never charged.